JP Morgan Upgrades CytomX Therapeutics to Overweight, Raises Price Target to $12

Benzinga Newsdesk www.benzinga.com Positive 90.5%

Neg 0% Neu 0% Pos 90.5%

JP Morgan analyst Anupam Rama upgrades CytomX Therapeutics (NASDAQ:CTMX) from Neutral to Overweight and raises the price target from $7 to $12.